Media
| Press Releases
KBP as Corporate Supporter of the KDCT 2025 Workshop
KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a clinical-stage biotechnology compa...
Apr 15, 2025
KBP将对诺和诺德申请获得的禁令进行抗辩
新加坡, 2025年2月28日/-- KBP Biosciences Pte. Ltd. （以下简称“KBP”）今日发表声明，回应新加坡国际商事法院（SICC）近期作出的裁决。SICC于2025年2月...
Feb 28, 2025
KBP to Contest Injunction Obtained by Novo Nordisk
SINGAPORE, February 28, 2025 / -- KBP Biosciences Pte. Ltd. (the “Company”) today issued a statement...
Feb 28, 2025
KBP Biosciences Announces Support of Kidney Disease Clinical Trialists 2024 Work...
SINGAPORE,27 March2024 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a clinical...
Mar 27, 2024
KBP Biosciences Announces Completion of Enrollment to its Phase 3 CLARION-CKD St...
PRINCETON, N.J., 31 October 2023 -- KBP Biosciences PTE, Ltd. (“KBP Biosciences”), a clinical-stage ...
Nov 02, 2023
Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosc...
Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. t...
Oct 16, 2023
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic K...
EMJ Nephrology interviewed two World-renowned experts in nephrology and cardiology, George Bakris an...
Apr 18, 2023
KBP Biosciences Announces First Patient Dosed in China
PRINCETON, N.J., 31 March 2023 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a ...
Mar 31, 2023
Ocedurenone Featured at Kidney Disease Clinical Trialists 2023 Workshop: Insight...
PRINCETON, N.J., 17 March 2023 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a ...
Mar 17, 2023
Ocedurenone (KBP-5074) Featured at the 19th Cardiovascular Clinical Trialists Fo...
PRINCETON, N.J., 10 February 2023 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”),...
Feb 13, 2023
KBP Presents Ocedurenone Clinical Pharmacology Studies at ASN Kidney Week 2022
PRINCETON, N.J., 2 December2022 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a...
Dec 02, 2022
KBP Presents Ocedurenone Phase 2b Subgroup Analysis at AHA Scientific Sessions 2...
PRINCETON, N.J., 1 December 2022 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), ...
Dec 01, 2022